Liquid chromatographic determination of indolidan and its dehydro metabolite in plasma. Use of the Varian AASP for solid-phase extraction.
A method is described for the determination of indolidan and its dehydro metabolite in human plasma. Two procedures are given, one manual and one which is semi-automated by use of the Varian AASP (Automated Analytical Sample Processor). The method involves solid-phase extraction to isolate the drug, metabolite, and an internal standard from plasma. The manual procedure requires elution of the analytes from the extraction column with methanol, evaporation of the methanol to dryness, and reconstitution in mobile phase prior to injection into a reversed-phase liquid chromatographic system. Using the AASP (semi-automated procedure), the analytes are eluted from the extraction column directly into the chromatographic system, resulting in substantial savings in sample preparation time. The limit of detection for both drug and metabolite is 0.25 ng/ml in plasma. Detection was made by ultraviolet absorbance, using wavelength programming to optimize the sensitivity of the assay for each compound.
Hamilton
M
M
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
D001322:Autoanalysis; D002316:Cardiotonic Agents / Q000097:blood* / Q000493:pharmacokinetics; D002849:Chromatography, Gas; D006801:Humans; D007202:Indicators and Reagents; D007211:Indoles / Q000097:blood* / Q000493:pharmacokinetics; D000078183:Oxindoles; D011724:Pyridazines / Q000097:blood* / Q000493:pharmacokinetics; D012997:Solvents; D013056:Spectrophotometry, Ultraviolet
D002316:Cardiotonic Agents; D007202:Indicators and Reagents; D007211:Indoles; D000078183:Oxindoles; D011724:Pyridazines; D012997:Solvents; C050325:indolidan